Fluticasone: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #26 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Corticosteroids]] | |||
[[Category:Glucocorticoids]] | |||
[[Category:Inhaled corticosteroids]] | |||
Latest revision as of 10:43, 23 May 2026
Fluticasone
Flonase (intranasal, OTC); Flovent (inhaled, asthma); Cutivate (topical)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Asthma controller0, Allergic rhinitis0, COPD0, Inflammatory dermatoses (topical)0
Pharmacy
Starting dose
Inhaled (Flovent HFA) 88 mcg BID; intranasal (Flonase) 2 sprays/nostril daily; topical (Cutivate) 0.05% cream BID
Preparations
Inhaled MDI 44/110/220 mcg per actuation; DPI (Diskus) 50/100/250 mcg; nasal spray 50 mcg/actuation; cream/ointment 0.005%, 0.05%
US FDA Max
ICS 880 mcg/d (asthma); intranasal 200 mcg/d
Pharmacology
Routes
Inhaled, intranasal, topical
Onset
Inhaled: bronchial effect 1-2 weeks; nasal: symptom relief 12-24 hours; topical: hours
Duration
12-24 hours per dose
Half-life
~7.8 hours (fluticasone propionate, inhaled systemic exposure)[1]
Bioavailability
<1% oral (extensive first-pass via CYP3A4); ~30% inhaled lung deposition[1]
Pregnancy
Inhaled and intranasal generally considered safe; widely used in asthma in pregnancy.[citation needed]
Legal status
OTC (intranasal Flonase) and Rx-only (inhaled, topical) in US
Purported mechanism
Fluticasone is a potent topical glucocorticoid receptor agonist designed for high local receptor affinity and extensive hepatic first-pass to minimize systemic glucocorticoid exposure.0 Suppresses inflammatory gene transcription (NF-κB, AP-1), induces lipocortin, downregulates mast cells and eosinophils. CYP3A4 substrate; strong CYP3A4 inhibitors (ritonavir, ketoconazole) can raise systemic levels enough to produce iatrogenic Cushing's[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Flovent HFA (fluticasone propionate), GlaxoSmithKline, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020548s055lbl.pdf